Middle East Breast Cancer Therapeutics Market Report 2022 to 2030

Middle East Breast Cancer Therapeutics Market Analysis

$ 3999

The Middle East breast cancer therapeutics market is expected to grow from $0.72 Bn in 2022 to $2.06 Bn in 2030 with a CAGR of 13.9% for the forecasted year 2022-2030. The main factors contributing to this market growth are public awareness about the treatment options and increased funding for clinical trials for breast cancer medications in the Middle East. The market is segmented by therapy, by cancer type, and by distribution channel. The main competitors in the Middle East breast cancer therapeutics market are Novartis, Mylan, and Eli Lilly.

ID: IN10MEPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Middle East AUTHOR: Parul Choudhary

Buy Now

Middle East Breast Cancer Therapeutics Market Executive Analysis

The Middle East breast cancer therapeutics market size is at around $0.72 Bn in 2022 and is projected to reach $2.06 Bn in 2030, exhibiting a CAGR of 13.9% during the forecast period. A recent analysis of the industry predicts that by 2022, healthcare spending in the Middle East will amount to roughly $89 Bn. The Middle East's healthcare systems have undergone significant advances over the previous 20 years. In the same period, infant mortality decreased from 69 deaths per 1,000 live births to 18, while life expectancy increased from 60.5 years in 1978 to 73 years in 2004. Governments are shifting away from investing in and operating healthcare facilities and more toward regulating and policy-making, in addition to the obvious regulatory changes and the significant move toward improving quality, efficiency, and cost.

Over 520,000 women die from breast cancer each year, despite significant efforts at early detection and novel treatments. Breast cancer risk factors include older age, particularly postmenopausal status, early menarche, delayed first pregnancy, reduced parity, and shorter nursing duration. They also include a family history of breast cancer. Concerns have been expressed in particular about the Middle East's apparent rise in breast cancer rates. Various systemic treatments may be used to treat metastatic breast cancer in women. Chemotherapy, hormone replacement treatment, biologics, immunotherapies, additional targeted medicines, or mixtures of these are examples of these. Adjuvant systemic therapy helps many women after surgery in the Middle East. This therapy aims to lower the possibility of breast cancer recurrence or metastasizing. Neoadjuvant treatment is a method that helps the tumor shrink and makes it simpler to remove surgically. The primary goal in each of these cases is to prevent the spread of invisible tiny metastases by killing or controlling them early. In the years following surgery, this lowers the likelihood of distant breast cancer spread.

middle east breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

Rising breast cancer cases and public awareness of available treatments are the main factors fuelling the Middle East breast cancer therapeutics market expansion. Increased funding and investments in clinical trials and health infrastructure are also accelerating the Middle East breast cancer therapeutics market growth.

Market Restraints

The Middle East breast cancer therapeutics market may be hindered by issues like high treatment costs, a lack of qualified medical oncologists, and complicated and time-consuming therapy procedures.

Competitive Landscape

Key Players

AstraZeneca
Pfizer
F. Hoffman - La Roche
Novartis
Mylan
Eli Lilly
Celgene
Sanofi
Johnson & Johnson

Healthcare Policies and Regulatory Landscape

Policies regarding breast cancer healthcare in the Middle East differ from nation to nation. While some nations in the region rely more on private health insurance and out-of-pocket costs, several in the region have comprehensive national health insurance schemes that cover the cost of breast cancer treatment. For example, the government of the UAE offers its residents' health insurance, which includes reimbursement for the cost of breast cancer treatment. Citizens' medical expenses for breast cancer treatment are covered by the Saudi Arabian government's national health insurance program. Private health insurance is also readily accessible and in Lebanon, the majority of people rely on private health insurance to pay for the expense of breast cancer treatment because the government only offers a small amount of coverage.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.